Lytix Biopharma AS (OSL:LYTIX)
Norway
· Delayed Price · Currency is NOK 8.90
-0.10 (-1.11%)
Jun 27, 2025, 4:25 PM CET
Lytix Biopharma AS Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Cash & Equivalents | 117.9 | 130.79 | 27.37 | 94.55 | 197.28 | 28.45 | Upgrade
|
Short-Term Investments | - | - | 23.18 | 50.61 | - | - | Upgrade
|
Cash & Short-Term Investments | 117.9 | 130.79 | 50.55 | 145.16 | 197.28 | 28.45 | Upgrade
|
Cash Growth | 350.49% | 158.75% | -65.18% | -26.42% | 593.43% | 122.33% | Upgrade
|
Accounts Receivable | - | 0.46 | - | - | - | - | Upgrade
|
Other Receivables | 9.36 | 12.1 | 12.12 | 6 | 5.13 | 3.63 | Upgrade
|
Receivables | 9.36 | 12.56 | 12.12 | 6 | 5.13 | 3.63 | Upgrade
|
Prepaid Expenses | - | 0.55 | 0.66 | 0.74 | 0.55 | 0.54 | Upgrade
|
Other Current Assets | - | - | 0 | - | - | -0 | Upgrade
|
Total Current Assets | 127.26 | 143.9 | 63.33 | 151.89 | 202.96 | 32.62 | Upgrade
|
Property, Plant & Equipment | 2.83 | 2.63 | 0.55 | 1.38 | 2.14 | - | Upgrade
|
Other Long-Term Assets | - | - | - | 0 | - | - | Upgrade
|
Total Assets | 130.09 | 146.54 | 63.87 | 153.27 | 205.1 | 32.62 | Upgrade
|
Accounts Payable | 5.83 | 5.02 | 3.57 | 7 | 1.48 | 3.28 | Upgrade
|
Accrued Expenses | - | 24.44 | 2.38 | 2.11 | 3.77 | 4.63 | Upgrade
|
Current Portion of Leases | 0.92 | 0.76 | 0.45 | 0.87 | 0.83 | - | Upgrade
|
Current Income Taxes Payable | - | 1.19 | 1.36 | 0.95 | 2.03 | 2.85 | Upgrade
|
Other Current Liabilities | 26.21 | 5.36 | 4.74 | 6.83 | 6.06 | 1.97 | Upgrade
|
Total Current Liabilities | 32.96 | 36.76 | 12.51 | 17.76 | 14.17 | 12.73 | Upgrade
|
Long-Term Leases | 1.96 | 1.88 | 0.04 | 0.48 | 1.34 | - | Upgrade
|
Other Long-Term Liabilities | - | -0 | - | - | - | - | Upgrade
|
Total Liabilities | 34.92 | 38.64 | 12.56 | 18.24 | 15.51 | 12.73 | Upgrade
|
Common Stock | 6.83 | 6.82 | 4.01 | 4.01 | 3.87 | 2.62 | Upgrade
|
Additional Paid-In Capital | 88.35 | 101.08 | 47.31 | 131.03 | 185.72 | 17.27 | Upgrade
|
Comprehensive Income & Other | - | - | - | - | -0 | - | Upgrade
|
Shareholders' Equity | 95.17 | 107.89 | 51.32 | 135.03 | 189.59 | 19.89 | Upgrade
|
Total Liabilities & Equity | 130.09 | 146.54 | 63.87 | 153.27 | 205.1 | 32.62 | Upgrade
|
Total Debt | 2.88 | 2.64 | 0.49 | 1.34 | 2.17 | - | Upgrade
|
Net Cash (Debt) | 115.02 | 128.15 | 50.06 | 143.81 | 195.11 | 28.45 | Upgrade
|
Net Cash Growth | 343.71% | 156.01% | -65.19% | -26.29% | 585.80% | 122.33% | Upgrade
|
Net Cash Per Share | - | 2.37 | 1.25 | 3.63 | 5.88 | 1.08 | Upgrade
|
Filing Date Shares Outstanding | - | 68.26 | 40.07 | 40.07 | 40.07 | 26.23 | Upgrade
|
Total Common Shares Outstanding | - | 68.16 | 40.07 | 40.07 | 38.74 | 26.23 | Upgrade
|
Working Capital | 94.3 | 107.14 | 50.81 | 134.13 | 188.8 | 19.89 | Upgrade
|
Book Value Per Share | - | 1.58 | 1.28 | 3.37 | 4.89 | 0.76 | Upgrade
|
Tangible Book Value | 95.17 | 107.89 | 51.32 | 135.03 | 189.59 | 19.89 | Upgrade
|
Tangible Book Value Per Share | - | 1.58 | 1.28 | 3.37 | 4.89 | 0.76 | Upgrade
|
Machinery | - | 0.2 | 0.2 | 0.15 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.